Tumor necrosis factor-α regulates angiogenesis of BeWo cells via synergy of PlGF/VEGFR1 and VEGF-A/VEGFR2 axes
Introduction
Tumor microenvironment plays an important role in tumor progression. It has been accepted that a close interaction of cancer cells with the inflammatory microenvironment contributes to tumor growth and survival [1,2]. Tumor necrosis factor-alpha (TNF-α) is a potent pro-inflammatory cytokine and was originally reported as a cytotoxic molecule that induces apoptosis [3,4]. A high-dose of TNF-α confers anti-tumor activity and has been used for treatment of solid tumors [5]. By contrast, there is growing evidence to suggest that a low-dose of TNF-α acts as a tumor promoter [6,7]. Shaarawy et al. reported that patients with progressive choriocarcinoma had a significant elevation of serum TNF-α [8]. However, the underlying mechanism of the tumor promoting activity induced by TNF-α in choriocarcinomas has remained unknown. Various mechanisms have been suggested by which TNF-α promotes tumor growth, including enhancing autocrine growth, invasion, and angiogenesis [6]. Angiogenesis is an essential process for the spread of tumors and the increased expressions of proangiogenic factors are associated with tumor growth. TNF-α is able to promote tumor angiogenesis by inducing various proangiogenic factors [6,9,10].
BeWo cells were originally derived from human choriocarcinoma and established as a cell line to study endocrine function in vitro [11]. There has been little evidence on the effects of TNF-α on BeWo cells. We have previously reported that a low-dose of TNF-α stimulated proliferation and promoted survival of BeWo cells, partially in combination with insulin-like growth factor-I [12]. In the present study, we investigated the effects of TNF-α on the angiogenesis of choriocarcinomas using BeWo cells.
Vascular endothelial growth factor-A (VEGF-A) and placental growth factor (PlGF) are both members of the VEGF family and are known to be produced by choriocarcinomas [13]. PlGF binds to VEGF receptor 1 (VEGFR1/Flt-1) selectively, while VEGF-A can bind both to VEGFR1 and VEGF receptor 2 (VEGFR2/Flk-1) [14,15]. Both PlGF and VEGF-A have been proposed to play an important role in the regulation of endothelial angiogenesis [16].
In this study, we investigated the effects of TNF-α on the production of PlGF and VEGF-A in BeWo cells. Furthermore, we also sought to elucidate the angiogenetic roles of PlGF and VEGF-A in the microenvironment of BeWo cells and the endothelial cells.
Section snippets
Materials
Human recombinant PlGF was purchased from PeproTech (Rocky Hill, NJ, USA). Human recombinant VEGF-A was purchased from ORF Genetics (Kopavogur, Iceland). NF-kB activation inhibitor IV (sc-222063) was purchased from Santa Cruz Biotechnology (Dallas, TX, USA).
Anti-VEGFR1/Flt-1 polyclonal antibody (AF321) for the blockage of receptor-ligand interaction was purchased from R & D Systems (Minneapolis, MN, USA). Anti-VEGFR1/Flt-1 polyclonal antibody (13687-1-AP) for immunoprecipitation and western
Effect of TNF-α on PlGF, VEGF-A, and sFlt-1 in BeWo cells
To evaluate the effects of TNF-α on the secretions of PlGF and VEGF-A by BeWo cells, the concentrations of the growth factors in the conditioned media were measured by ELISA. As shown in Fig. 1A, the concentrations of PlGF were significantly higher in the presence of 10 and 102 pg/mL of TNF-α (22.0 ± 0.6 ng/mL, p < 0.05; 20.8 ± 1.3 ng/mL, p < 0.05) compared with the control (17.6 ± 0.5 ng/mL), while VEGF-A concentrations were not affected. When incubated with 105 pg/mL of TNF-α, the secretions
Discussion
In the present study, we revealed that TNF-α promoted PlGF synthesis of BeWo cells and regulated angiogenesis via synergy of PlGF/VEGFR1 and VEGF-A/VEGFR2 axes.
First, low levels (10–102 pg/mL) of TNF-α enhanced PlGF synthesis both in protein and mRNA expression levels, while the changes in VEGF-A were not significant. Although the effects of TNF-α on VEGF-A synthesis in trophoblast-derived cell lines have been investigated [17,18], there is little evidence on the effects on PlGF. Kato et al.
Funding
This work was supported by JSPS KAKENHI JP17K18083.
Conflicts of interest
There are no conflicts of interest, sources of financial support, corporate involvement, patent holdings for each author to be disclosed.
Acknowledgement
The authors wish to thank Manami Ishida for her technical support in the experiments conducted in the current study.
References (30)
- et al.
Cytokines as a key component of cancer-related inflammation
Cytokine
(2008) - et al.
Synthesis and release of platelet-activatig factor by human vascular endothelial cells treated with tumor necrosis factor or interleukin 1 alpha
J. Biol. Chem.
(1988) - et al.
Synergistic effects of tumor necrosis factor-α and insulin-like growth factor-I on survival of human trophoblast-derived BeWo cell line
Growth Hormone IGF Res.
(2018) VEGF receptor protein-tyrosine kinases: structures and regulation
Biochem. Biophys. Res. Commun.
(2008)- et al.
Signal transduction by VEGF receptors in regulation of angiogenesis and lymphangiogenesis
Exp. Cell Res.
(2006) - et al.
Expression and regulation of vascular endothelial growth factor in a first trimester trophoblast cell line
Placenta
(2000) - et al.
Placenta growth factor. Potentiation of vascular endothelial growth factor bioactivity, in vitro and in vivo, and high affinity binding to Flt-1 but not to Flk-1/KDR
J. Biol. Chem.
(1994) - et al.
IKKbeta links inflammation and tumorigenesis in a mouse model of colitis-associated cancer
Cell
(2004) - et al.
Inflammation and cancer
Nature
(2002) - et al.
An endotoxin-induced serum factor that causes necrosis of tumors
Proc. Natl. Acad. Sci. U.S.A.
(1975)